重组人干扰素α 1b治疗风疹58例临床观察

目的 观察重组人干扰素α1b治疗风疹的临床疗效.方法 116例风疹患儿随机分为治疗组和对照组,治疗组58例采用重组人干扰素α1b治疗,按年龄给予不同剂量,小于1岁,5ug/日,肌注一日一次；1-5岁,10 ug/日,肌注一日一次；6-14岁,20ug/日,肌注一日一次,疗程3-5天；对照组给予利巴韦林10 mg/（kg.d）静脉滴注,每日一次或分两次肌注,疗程3-5天.比较两组的疗效及不良反应.结果 治疗组总有效率98.27％；对照组89.65％；两组比较差异具有统计学意义（P＜0.05）,两组均未见不良反应.结论 重组人干扰素α1b治疗风疹的临床疗效好.

Objective To observe the clinical effect of recombinant human interferon alpha lb treatment of rubella. Methods 116 cases of measles were randomly divided into treatment group and control group, 58 cases in treatment group with recombinant human interferon alpha lb treatment, given the different doses according to age, less than 1 years old, 5ug/day, intramuscular injection once a day~ 1-5 years old, 10 ug/days, intramuscular injection once a day; 6-14, 20ug/day, intramuscular injection once a day, 3-5 days treatment; the control group was given the Leigh Bhave Lin 10 mg/（ kg.d ） intravenously, once a day or two intramuscular injection, treatment 3-5 days. The efficacy and adverse reaction were compared between the two groups. Results in the treatment group, the total efficiency of 98.27%; control group 89.65%; the difference between the two groups was statistically significant （ P 〈 0.05 ）, the two groups had no adverse reaction. Conclusion The curative effect of recombinant human interferon alpha lb treatment of rubella is best.